focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXeris Biopharma Regulatory News (0A8E)

Share Price Information for Xeris Biopharma (0A8E)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.056574
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2.001594
0A8E Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Xeris Pharmaceuticals, Inc Amend 8.3

26 Aug 2021 18:19

RNS Number : 9478J
J.P. Morgan Securities LLC
26 August 2021
 

Ap19

 

 

 

AMENDMENT

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1. KEY INFORMATION

 

Name of person dealing (Note 1)

J.P. Morgan Securities LLC

Company dealt in

Xeris Pharmaceuticals, Inc.

Class of relevant security to which the dealings being disclosed relate (Note 2)

$0.001 common stock

Date of dealing

06 August 2021

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

4,033,591 6.07

134,463 0.20

(2) Derivatives (other than options)

124,443 0.19

(3) Options and agreements to purchase/sell

Total

4,158,034 6.26

134,463 0.20

 

 

 

1. DEALINGS (Note 4)

 

(a) Purchases and sales

 

 

Purchase/sale

 

Number of relevant securities

 

Price per unit (USD)

 

(Note 5)

Purchase(New Borrow)

 

Purchases

 

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

28,800

 

1,770,701

 

 1,500

 1,700

 100

 52,776

 799

 700

 21,146

 378

 4,878

 22,327

 3,814

 2,699

 2,495

 13,813

 1,869

 38,178

 36,716

 23,900

 22,938

 2,964

 5,800

 23,489

 1,257

 11,666

 3,198

 21,336

 19,376

 30,753

 6,845

 13,200

 7,502

 14,350

 5,926

 3,641

 5,822

 3,952

 6,377

 11,000

 4,357

 2,151

 5,000

 3,900

 1,500

 57,400

 5,145

 12,384

 193

 1,099

 29,593

 900

 18,018

 693

 10,768

 19,067

 5,307

 1,460

 2,780

 1,100

 4,119

 799

 3,446

N/A

 

2.4000 USD

2.3100 USD

2.3125 USD

2.3150 USD

2.3156 USD

2.3187 USD

2.3200 USD

2.3204 USD

2.3250 USD

2.3300 USD

2.3306 USD

2.3332 USD

2.3339 USD

2.3350 USD

2.3358 USD

2.3400 USD

2.3401 USD

2.3429 USD

2.3442 USD

2.3450 USD

2.3500 USD

2.3502 USD

2.3509 USD

2.3513 USD

2.3541 USD

2.3542 USD

2.3550 USD

2.3572 USD

2.3573 USD

2.3600 USD

2.3609 USD

2.3622 USD

2.3627 USD

2.3634 USD

2.3650 USD

2.3690 USD

2.3700 USD

2.3748 USD

2.3750 USD

2.3763 USD

2.3800 USD

2.3850 USD

2.3867 USD

2.3903 USD

2.3950 USD

2.4000 USD

2.4035 USD

2.4050 USD

2.4100 USD

2.4135 USD

2.4144 USD

2.4183 USD

2.4200 USD

2.4207 USD

2.4263 USD

2.4312 USD

2.4438 USD

2.4500 USD

2.4550 USD

2.5200 USD

2.5250 USD

2.5300 USD

 

 

 

(b) Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(USD) (Note 5)

 

 

 

(c) Options transactions in respect of existing relevant securities

 

 

(i) Writing, selling, purchasing or varying

 

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

(ii) Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

Ap21

 

2. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

None

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)  NO

 

Date of disclosure

 26 August 2021

Contact name

Alwyn Basch

Telephone number

0207 742 7407

If a connected EFM, name of offeree/offeror with which connected

N/A

If a connected EFM, state nature of connection (Note 10)

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISESEWFWMEFSEFA
Date   Source Headline
9th Jul 202112:24 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
9th Jul 202111:08 amGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
9th Jul 202110:06 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
8th Jul 20214:18 pmGNWInvesco ltd: Form 8.3 - Xeris Pharmaceuticals Plc.
8th Jul 20213:20 pmRNSForm 8.3 -Xeris Pharmaceuticals, Inc.
8th Jul 20212:38 pmRNSXeris Pharmaceuticals, Inc 8.3
8th Jul 202112:27 pmGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
8th Jul 202111:09 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
7th Jul 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
7th Jul 20212:57 pmRNSXeris Pharmaceuticals, Inc 8.3
7th Jul 20211:04 pmGNWInvesco ltd: Form 8.3 - Xeris Pharmaceuticals Plc.
7th Jul 202112:46 pmGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
6th Jul 20216:12 pmRNSXeris Pharmaceuticals Inc Amend 8.3
5th Jul 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
5th Jul 202112:29 pmRNSXeris Pharmaceuticals Inc 8.3
5th Jul 202110:54 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
2nd Jul 20212:56 pmRNSXeris Pharmaceuticals, Inc 8.3
2nd Jul 20211:05 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
2nd Jul 202111:11 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
1st Jul 20212:38 pmRNSXeris Pharmaceuticals, Inc 8.3
1st Jul 20211:56 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
1st Jul 202112:42 pmGNWInvesco ltd: Form 8.3 - Xeris Pharmaceuticals, Inc.
1st Jul 202110:20 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
30th Jun 20215:46 pmRNSXeris Pharmaceuticals Inc Amnd 8.3
30th Jun 20211:37 pmRNSXeris Pharmaceuticals, Inc 8.3
30th Jun 202112:58 pmGNWInvesco ltd: Form 8.3 - Xeris Pharmaceuticals, Inc.
29th Jun 20213:15 pmBUSForm 8.3 - Xeris Pharmaceuticals, Inc.
29th Jun 20213:07 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
29th Jun 20211:13 pmRNSXeris Pharmaceuticals, Inc 8.3
29th Jun 202111:47 amRNSForm 8.3 - Xeris Pharmaceuticals, Inc
29th Jun 202111:03 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
29th Jun 20217:53 amGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
28th Jun 20216:05 pmRNSXeris Pharmaceuticals Inc Amnd 8.3
28th Jun 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals Inc
28th Jun 20213:15 pmBUSForm 8.3 - Xeris Pharmaceuticals, Inc.
28th Jun 20212:52 pmRNSXeris Pharmaceuticals, Inc 8.3
28th Jun 20212:43 pmGNWInvesco ltd: Form 8.3 - Xeris Pharmaceuticals, Inc.
28th Jun 20212:29 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
28th Jun 202112:01 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
25th Jun 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals Inc
25th Jun 20212:37 pmRNSXeris Pharmaceuticals Inc 8.3
25th Jun 20212:24 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
25th Jun 202112:52 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
25th Jun 202110:46 amGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
24th Jun 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals Inc
24th Jun 20212:50 pmGNWInvesco ltd: Form 8.3 - Xeris Pharmaceuticals, Inc.
24th Jun 20212:50 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
24th Jun 20212:39 pmRNSXeris Pharmaceuticals Inc 8.3
24th Jun 20212:39 pmGNWForm 8.3 - Xeris Pharmaceuticals Inc
24th Jun 20212:22 pmGNWForm 8.3 -Strongbridge Biopharma plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.